Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 4/20 | 0.34 |
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | SELP | P16109 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.32 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4543547 | 0.82 | CYP1A2 (0.32) | CYP1A2CYP2C19MAPTCYP3A4CYP2C9 | |
| SCHEMBL4390910 | 0.71 | MAPT (0.61) | CYP1A2CYP2C19MAPTCYP3A4CYP2C9 | |
| SCHEMBL2171264 | 0.71 | NPC1 (0.55) | CYP1A2CYP2C19MAPTCYP3A4CYP2C9 | |
| SCHEMBL5670554 | 0.68 | MAPT (0.59) | CYP1A2CYP2C19MAPTCYP3A4CYP2C9 | |
| SCHEMBL2220055 | 0.67 | MAPT (0.36) | CYP1A2CYP2C19MAPTCYP3A4CYP2C9 | |
| SCHEMBL2175901 | 0.67 | SCN2A (0.47) | CYP1A2CYP2C19MAPTCYP3A4CYP2C9 | |
| SCHEMBL4563131 | 0.66 | MAPT (0.40) | CYP1A2CYP2C19MAPTCYP3A4CYP2C9 | |
| SCHEMBL2176692 | 0.66 | MAPT (0.52) | CYP1A2CYP2C19MAPTCYP3A4CYP2C9 | |
| SCHEMBL2173835 | 0.66 | NPC1 (0.46) | MAPTCACNA1GCACNA1HCACNA1IALDH1A1 | |
| SCHEMBL4543938 | 0.66 | MAPT (0.41) | CYP1A2CYP2C19MAPTCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | ALK, BCL3, MCL1 | TYRO3 247/4885MET 148/4885SELP 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.